Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Asthma
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is one of the most prevalent chronic respiratory diseases in children, and accurate phenotyping and disease monitoring remain challenging in routine clinical practice. This observational cohort study aims to investigate the clinical value of multimodal tongue and pulse information in the syndrome diagnosis and phenotypic characterization of pediatric asthma. Children aged 5-18 years with a confirmed diagnosis of asthma will be enrolled at Shanghai Children's Medical Center and followed in routine outpatient care. Standardized tongue images and pulse wave data will be collected using validated acquisition devices during visits when lung function testing is performed. Quantitative features extracted from tongue and pulse data will be integrated with clinical information, including asthma stage, lung function parameters, eosinophil counts, allergic sensitization status, and Asthma Control Questionnaire-5 (ACQ-5) scores. The primary objective is to evaluate the associations between tongue-pulse multimodal features and asthma clinical stages and pulmonary function. Secondary objectives include exploring their relationships with airway inflammation and asthma control status. This study seeks to establish a non-invasive, objective, and quantifiable approach to asthma phenotyping, providing evidence for integrating traditional diagnostic features with modern clinical data to support precision management of pediatric asthma.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention (observational study) — No intervention (observational study)

Primary Outcomes

  • Association Between Tongue-Pulse Multimodal Features and Pulmonary Function in Pediatric Asthma (During routine outpatient visits at baseline and follow-up when pulmonary function testing is performed (up to 12 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-01
Completion: 2028-01-31
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Children's Medical Center
Principal Investigators:
  • Yong Yin (PRINCIPAL_INVESTIGATOR) - Shanghai Children's Medical Center
Contact Information
Study Contact:
Yong Yin
86-021-38626161
yinyong9999@163.com
Yong Yin, PhD
8618930830705
yinyong9999@163.com
Shanghai Children's Medical Center
Interventions
  • Other: No intervention (observational study) — No intervention (observational study)
Study Locations (1 sites)
Shanghai Children's Medical Center, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Children aged 5 to 18 years. * Clinically diagnosed asthma according to established pediatric asthma guidelines. * Receiving routine outpatient follow-up at Shanghai Children's Medical Center. * Able to cooperate with tongue image acquisition and pulse wave data collection. * Able to perform pulmonary function testing when clinically indicated. * Written informed consent obtained from parents or legal guardians, with assent from the child when appropriate. Exclusion Criteria: * Presence of other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis, primary ciliary dyskinesia). * Congenital cardiopulmonary malformations or significant cardiovascular disease. * Acute respiratory infection or fever at the time of data collection. * Severe systemic diseases or immunodeficiency that may affect study participation. * Inability to comply with study procedures or incomplete clinical data.
Conditions Bronchiolitis Acute, Lower Respiratory T...
Phase Not Applicable
Enrollment 200
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Lower respiratory tract infections (LRTIs) are a significant cause of childhood morbidity and mortality globally, particularly in low-income countries. In Norway, LRTIs is a leading cause of hospitalization among infants, representing a great socioeconomic burden. Bronchiolitis, a viral infection, is the main representation of LRTIs in infants. It affects the small airways, causing breathing- and feeding difficulties. Today, treatment relies on subjective evaluations, lacking objective measures for assessment. This increases the risk of both under- and over treating patients. In the long term, bronchiolitis increases risk of asthma, but it is unknown who the high-risk patients for chronic lung disease are. Lung ultrasonography (LUS) has emerged as a promising tool for assessing bronchiolitis severity and progression of the disease. The investigators will explore its use to improve diagnostic accuracy and treatment decisions, and develop AI-driven scoring tools for novel technology. Additionally, tidal breathing flow volume loops (TBFVL) offer a non-invasive method for evaluating airway obstruction in infants, with the potential to assess severity of bronchiolitis, treatment efficacy and post-infection lung function. In this project the investigators will combine the use of these modern technologies to improve treatment and follow-up of infants with LRTIs. The main aim for this observational study is to assess the utility of lung ultrasonography (LUS) and tidal flow volume loops (TBFVL) in infant lower respiratory tract infections (LRTIs) for individual risk stratification in acute and chronic settings. This aims to refine the management of bronchiolitis, identifying high-risk patients for chronic lung disease to tailor treatment and follow-up protocols. The project has three secondary objectives. 1. To assess correlation between LUS and TBFVL findings with clinical score at admission, length of stay, need of respiratory support and ICU admissions. 2. To assess duration of symptoms following acute bronchiolitis and evaluate the use of LUS and TBFVL in objectively examine post-infectious sequela. 3. To evaluate the long-term impact of bronchiolitis on lung function through clinical follow-up after a 12 month period. Lower respiratory tract infections (LRTIs) stand as the leading cause of hospitalization, while asthma is the leading cause of chronic lung disease among children in Nordic countries. The project seeks to improve risk stratification and treatment protocols in both acute and chronic settings. In the acute setting, the project endeavors to prognosticate individual patient outcomes, thereby individualize treatment and mitigating unnecessary hospital admissions, use of respiratory support and antibiotic administration. Additionally there is potential of more aggressive treatment to selected patients. The study aims to improve the understanding of pathophysiological processes of LRTIs in infants, providing objective metrics to…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: lung ultrasound — performance of lung utltrasound in participants, performed bedside (v scan).
  • Diagnostic Test: Tidal-flow volume loops — tidal-flow volume loops performed in patients hospitalized with lower respiratory tract infections.

Primary Outcomes

  • Number of readmissions at 1 year follow-up after baseline. (From enrollment to the end of follow-up at 12 months.)
  • Length of stay at hospital due to LRTI. (from enrollment to discharge from hospital, average patient is hospitalized 3 days.)
  • Duration of symptoms after hospitalization due to LRTI. (from enrollment to weeks/months after discharge, based on reporting of symptoms. Up to 60 days.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-15
Completion: 2029-06-30
Eligibility
Age: 0 Days and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Helse Møre og Romsdal HF
Collaborators: St. Olavs Hospital
Contact Information
Study Contact:
Hans Kristian S Ipsen, medical doctor
+4770105000
hans.kristian.ipsen@helse-mr.no
Kari Risnes, Professor
+4772573000
kari.risnes@ntnu.no
Hans Kristian S Ipsen, medical doctor
+4770105000
hans.kristian.ipsen@helse-mr.no
Aalesund Hospital
Interventions
  • Diagnostic Test: lung ultrasound — performance of lung utltrasound in participants, performed bedside (v scan).
  • Diagnostic Test: Tidal-flow volume loops — tidal-flow volume loops performed in patients hospitalized with lower respiratory tract infections.
Study Locations (2 sites)
Aalesund Hospital, Ålesund, Møre og Romsdal 6017 Norway
St. Olavs Hospital HF, Trondheim, Sør-Trøndelag 7030 Norway
Eligibility Criteria
Inclusion Criteria: * clinical diagnosis of lower respiratory tract infection * with tachypnea and/or * wheezing * Retractions * Respiratory difficulties Exclusion Criteria: * Severe Congenital heart disease (not ASD, small VSD, PDA) * Cystic fibrosis and PCD * Neuromuscular diseases and other diseases with reduced airway clearance * Severe malacia, diagnosed by bronchoscopy by time of T0. * Foreign body inhalation * Pneumothorax * Pleural effusion (with need of invasive interventions) * Bronchopulmonary dysplasia or GA \<32 weeks * Caretaker not able to communicate in Norwegian or English * Weight \<3 kg
Conditions Asthma
Phase Not Applicable
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is one of the most common chronic respiratory diseases. Previous study found a series of differentially expressed genes and proteins (transgelin-2, metallothionein-2, ezrin) in asthmatic rat. The aim of the study is to investigate the changes and associations of these gene with asthma in human.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Interventions / Regimen

  • Diagnostic Test: No intervention — No intervention

Primary Outcomes

  • Difference in gene expression of transgelin-2, metallothionein-2 and ezrin between controls and asthmatic patients (Two year)
  • Association of transgelin-2, metallothionein-2 and ezrin with asthma (Two year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-01
Completion: 2026-12
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai University of Traditional Chinese Medicine
Collaborators: Xiangya Hospital of Central South University, National Natural Science Foundation of China
Principal Investigators:
  • Lei-Miao Yin, MD (STUDY_CHAIR) - Yueyang Hospital, Shanghai University of Traditional Chinese medicine
  • Jun-Tao Feng, MD (STUDY_DIRECTOR) - Xiangya Hospital of Central South University
Contact Information
Study Contact:
Lei-Miao Yin, MD
13774384237
collegeylm@shutcm.edu.cn
Jun-Tao Feng, MD
13786145799
jtfeng1976@csu.edu.cn
Jun-Tao Feng, MD
13786145799
jtfeng1976@csu.edu.cn
Xiangya Hospital, Central South University
Interventions
  • Diagnostic Test: No intervention — No intervention
Study Locations (2 sites)
Xiangya Hospital, Central South University, Changsha, Hunan 410000 China
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality 200030 China
Eligibility Criteria
Inclusion Criteria: 1. Males or females, aged 14-75 years; 2. Patients with a definite diagnosis of bronchial asthma; 3. The diagnosis of asthma according to the Global Initiative for Asthma (GINA), with positive bronchodilator responsiveness (reversibility) test; 4. Healthy volunteers without respiratory symptoms such as cough, wheezing, chest tightness or dyspnea; 5. Agree with all procedures in this trial by signing a written informed consent form. Exclusion Criteria: 1. Patients with chronic obstructive pulmonary disease or other airway disease; 2. Complicated with other severe primary diseases (including hypertension, cancer, hyperthyroidism, bronchiectasia, cardiac insufficiency) and conditions that would prevent participation in the trial or put the participant at risk; 3. Women who are known to be pregnant or breastfeeding; 4. Not willing to participate; 5. Psychiatric history and neurological disorders can not work normally; 6. Other conditions that the researcher considers inappropriate to participate in this study.
Conditions Perinatal Depression, Perinatal Anxiety
Phase NA
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This study is part of the ERC-funded e-Perinatal project and represents a large-scale hybrid type 1 effectiveness-implementation cluster randomized controlled trial. The primary aim is to evaluate the effectiveness of a personalized and complex mobile health (mHealth) intervention (e-Perinatal) in the universal prevention of maternal perinatal depression and anxiety disorders. Secondary aims include evaluating the impact on paternal mental health and child development, as well as examining implementation outcomes in real-world primary healthcare settings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: The e-Perinatal intervention is a personalized mobile health (mHealth) program — The e-Perinatal intervention is a personalized mobile health (mHealth) program that includes: 1) Digital micro-interventions focused on psychological, physical activity, and healthy lifestyle domains; 2) a personalized recommendation engine; 3) a social support section; 4) mental health monitoring; 5) an 'SOS' button for assistance; and 6) an appointment reminder tool. The intervention is delivered through a mobile application and is integrated into routine maternal care. Participants will use the app from recruitment (pregnancy) until 12 months of postpartum.
  • Other: Standard routine maternal care — Participants will receive standard maternal care as provided by the public healthcare system, including routine antenatal and postnatal visits and access to maternal education programs.

Primary Outcomes

  • Cumulative incidence of maternal perinatal depression and anxiety disorders (Baseline and 12 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-15
Completion: 2028-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Seville
Collaborators: Junta de Andalucia, Andalusian Health Service
Principal Investigators:
  • Emma Motrico, PhD (PRINCIPAL_INVESTIGATOR) - University of Seville
Contact Information
Study Contact:
Emma Motrico, PhD Psychology
0034636995778
eperinatal@us.es
Ana Belén Naranjo Saucedo, MSc
+34 676426430
ana.naranjo@juntadeandalucia.es
Primary Health Care Center Mairena del Aljarafe - Ciudad Expo
Interventions
  • Behavioral: The e-Perinatal intervention is a personalized mobile health (mHealth) program — The e-Perinatal intervention is a personalized mobile health (mHealth) program that includes: 1) Digital micro-interventions focused on psychological, physical activity, and healthy lifestyle domains; 2) a personalized recommendation engine; 3) a social support section; 4) mental health monitoring; 5) an 'SOS' button for assistance; and 6) an appointment reminder tool. The intervention is delivered through a mobile application and is integrated into routine maternal care. Participants will use the app from recruitment (pregnancy) until 12 months of postpartum.
  • Other: Standard routine maternal care — Participants will receive standard maternal care as provided by the public healthcare system, including routine antenatal and postnatal visits and access to maternal education programs.
Study Locations (1 sites)
Primary Health Care Center Mairena del Aljarafe - Ciudad Expo, Mairena del Aljarafe, Sevilla 41927 Spain
Eligibility Criteria
Inclusion Criteria: \- Inclusion Criteria (Women) Must receive an invitation to participate from a healthcare professional at one of the participating primary healthcare centers Must be pregnant for at least 11 weeks at the time of enrollment Must be at least 18 years old Must have access to a mobile phone and internet connection Must be able to read, write, and understand Spanish Must have a personal email account No diagnosis of depression or anxiety disorder at baseline Forma \- Inclusion Criteria (Partners or significant others) Must receive an invitation to participate from a woman already enrolled in the study Must be at least 18 years old Must have access to a mobile phone and internet connection Must be able to read, write, and understand Spanish Must have a personal email account Exclusion Criteria: * Exclusion Criteria (Women) Current diagnosis of depression or anxiety disorder Receiving psychological or pharmacological treatment for mental health or substance use conditions \- Exclusion criteria for partners (or significant others): There are no exclusion criteria for partners
Conditions Premenstrual Syndrome, Premenstrual Dysp...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program * a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Lutea Transcranial Direct Current Stimulation (tDCS) Device — The Lutea device (Samphire Group, Inc.) is an FCC-registered consumer wellness wearable that delivers low-intensity transcranial direct current stimulation (tDCS) targeting the primary motor cortex (M1) and dorsolateral prefrontal cortex (DLPFC). Sessions are 20 minutes in duration at a recommended frequency of multiple sessions per week, self- administered at home. The device does not meet the FDA's statutory definition of a medical device; it is intended for general wellness purposes and is not cleared or approved for the diagnosis, cure, mitigation, treatment, or prevention of any disease.
  • Behavioral: Samphire Guided Care Program — A 12-week structured digital health program comprising: clinician-led neuromodulation eligibility assessment and care pathway assignment at onboarding; ongoing neuromodulation coach support; and app-based daily symptom tracking via the Alethios digital research platform. All participants in both groups receive this program component.

Primary Outcomes

  • Work Productivity and Activity Impairment (WPAI) - Overall Work Impairment (Baseline to Week 12)
  • EQ-5D-5L Utility Index Score (Baseline to Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Samphire Group, Inc.
Principal Investigators:
  • Nirav Shah, MD, MPH (PRINCIPAL_INVESTIGATOR) - Samphire Group, Inc.
Contact Information
Study Contact:
Nirav Shah, MD, MPH
6267201547
nirav@investigator.alethios.com
Zeenia Framroze
support@alethios.com
Zeenia Framroze
support@alethios.com
Alethios Digital Research Platform (Decentralized)
Interventions
  • Device: Lutea Transcranial Direct Current Stimulation (tDCS) Device — The Lutea device (Samphire Group, Inc.) is an FCC-registered consumer wellness wearable that delivers low-intensity transcranial direct current stimulation (tDCS) targeting the primary motor cortex (M1) and dorsolateral prefrontal cortex (DLPFC). Sessions are 20 minutes in duration at a recommended frequency of multiple sessions per week, self- administered at home. The device does not meet the FDA's statutory definition of a medical device; it is intended for general wellness purposes and is not cleared or approved for the diagnosis, cure, mitigation, treatment, or prevention of any disease.
  • Behavioral: Samphire Guided Care Program — A 12-week structured digital health program comprising: clinician-led neuromodulation eligibility assessment and care pathway assignment at onboarding; ongoing neuromodulation coach support; and app-based daily symptom tracking via the Alethios digital research platform. All participants in both groups receive this program component.
Study Locations (1 sites)
Alethios Digital Research Platform (Decentralized), San Francisco, California 94105 United States
Eligibility Criteria
Inclusion Criteria: * Self-identified female, aged 18-65 years at the time of enrollment * Basic English literacy * Able and willing to provide informed consent electronically * Residing in the United States * Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood) * Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships * Currently in full-time employment with medical benefits as part of compensation package * Access to a smartphone with internet access compatible with the Samphire mobile application * Able to safely operate the study device in the home environment * Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program Exclusion Criteria: * Pregnancy, breastfeeding, or actively planning pregnancy during the study period * History of epilepsy or seizure disorder * Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation * Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use * Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use * Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening * Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening * Inability to provide informed consent or safely use the device in the home environment * Current participation in another interventional neurotechnology or drug study
Conditions Interpersonal Trauma, Depression, PTSD, ...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: BEAR-SI — The BEAR Therapeutic program is a twelve-week group that meets once per week for 1.5 hours per week. The program includes three main components. The first is a psycho-educational component which provides current information about assault statistics, common risk factors, myths that are often associated assault, and safety related information The second component focuses on the development of an assortment of interpersonal skills. This part of the group offers skills such as assertiveness or communication training, boundary setting, and coping skills. The third component of our intervention consists of a thorough set of self-defense skills that help women to keep themselves safe. The repertoire of skills include recognizing unsafe situations, utilizing one's voice, and release from holds. This section provides ample practice blocks, resistance skills, and specific techniques to keep one's self safe.

Primary Outcomes

  • Coping self-efficacy (Baseline to 12 weeks (post-group))
  • Beck Scale for Suicidal Ideation (Baseline to 12 weeks (post-group))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-17
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Jennifer Keller, PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Clinical Research Coordinator
650-724-7184
bearstudy@stanford.edu
Clinical Research Coordinator
650-724-7184
bearstudy@stanford.edu
Stanford University School of Medicine
Jennifer Keller, PhD
Stanford University School of Medicine
Interventions
  • Behavioral: BEAR-SI — The BEAR Therapeutic program is a twelve-week group that meets once per week for 1.5 hours per week. The program includes three main components. The first is a psycho-educational component which provides current information about assault statistics, common risk factors, myths that are often associated assault, and safety related information The second component focuses on the development of an assortment of interpersonal skills. This part of the group offers skills such as assertiveness or communication training, boundary setting, and coping skills. The third component of our intervention consists of a thorough set of self-defense skills that help women to keep themselves safe. The repertoire of skills include recognizing unsafe situations, utilizing one's voice, and release from holds. This section provides ample practice blocks, resistance skills, and specific techniques to keep one's self safe.
Study Locations (1 sites)
Stanford University School of Medicine, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Women ages 18-75 * History of physical, sexual, and/or sexual emotional violence, with subsequent interpersonal or psychological distress (e.g., depression or anxiety) related to this history. * Current suicidal thinking Exclusion Criteria: * Active, significant substance abuse, which could interfere with participation * Significant medical conditions that would preclude safe participation in the study * No history of interpersonal trauma * Acute psychiatric instability * History of assaultive behavior or is judged to be a potential risk to assault others. * No current suicidal ideation or behaviors * Unable to commit to the group for 12 weeks in-person
Conditions Late-Life Adults, Late-Life Prodromal De...
Phase NA
Enrollment 124
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial will examine the effects of mindfulness-based interventions and brain stimulation interventions on cognitive function and psychological well-being in older adults. The study will employ a comprehensive assessment approach incorporating psychological evaluations, behavioral assessments, psychophysiological measurements, and neuroimaging analyses to characterize the outcome of nonpharmaceutical interventions in improving geriatric well-being or reducing depression severity.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: MBSR — Mindfulness-Based Stress Reduction
  • Behavioral: MBWC — Mindfulness-Based Well-Being Curriculum
  • Behavioral: MBCI — Mindfulness-Based Curriculum for Insomnia
  • Device: BSI — Brain Stimulation Intervention

Primary Outcomes

  • Changes in neural activation related to emotional processing, sensory processing, attention, and memory-related brain regions. (Baseline assessment conducted during the 4-week period prior to intervention initiation; follow-up assessment conducted during the 4-week period following intervention completion.)
  • Changes in resting-state functional connectivity within and between brain networks (Baseline assessment conducted during the 4-week period prior to intervention initiation; follow-up assessment conducted during the 4-week period following intervention completion.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-01
Completion: 2028-12
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: true
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Health Research Institutes, Taiwan
Contact Information
Study Contact:
Ai-Ling Hsu, PhD.
+886-5-6327369
alhsu@nhri.edu.tw
Changwei W. Wu, PhD.
+886-2-66202589
sleepbrain@tmu.edu.tw
Changwei W. Wu, PhD.
+886-2-66202589
sleepbrain@tmu.edu.tw
Shuang Ho Biomedical Park, Taipei Medical University
Interventions
  • Behavioral: MBSR — Mindfulness-Based Stress Reduction
  • Behavioral: MBWC — Mindfulness-Based Well-Being Curriculum
  • Behavioral: MBCI — Mindfulness-Based Curriculum for Insomnia
  • Device: BSI — Brain Stimulation Intervention
Study Locations (2 sites)
Shuang Ho Biomedical Park, Taipei Medical University, New Taipei City, 235603 Taiwan
National Center for Geriatrics and Welfare Research, Yunlin, 632007 Taiwan
Eligibility Criteria
Inclusion Criteria for individuals participating in mindfulness-based Interventions: * Literate or have received an education above the elementary level. * Have normal or corrected vision and hearing, able to communicate and understand explanations. * Right-handed individuals as assessed by the Edinburgh Handedness Inventory. Exclusion Criteria for individuals participating in mindfulness-based Interventions: * Individuals with dementia, stroke, cerebrovascular disease, brain injury, epilepsy, or Parkinson's disease. * Individuals with neurological system disorders. * Individuals with alcohol or drug dependence. * Individuals with other major physical illnesses, such as diabetes, heart failure, or endocrine abnormalities, or those who have experienced an acute myocardial infarction within the past three months. * Individuals with metal objects in the body that cannot undergo magnetic resonance imaging (MRI), such as cardiac pacemakers, vascular clips, hearing aids, artificial joints, steel pins, etc. * Individuals with Claustrophobia. * Individuals in pregnancy or possibility of pregnancy. Inclusion Criteria for individuals participating in brain stimulation Intervention: * Individuals diagnosed with major depressive disorder by psychiatrists according to the Diagnostic and Statistical Manual, and who can cooperate with the psychiatric outpatient clinic regulations. * Literate or have received an education above the elementary level. * Have normal or corrected vision and hearing, able to communicate and understand explanations. * Right-handed individuals as assessed by the Edinburgh Handedness Inventory. * Individuals are prescribed brain stimulation therapy by clinical physicians. Exclusion Criteria for individuals participating in brain stimulation Intervention: * Individuals with dementia, stroke, cerebrovascular disease, brain injury, epilepsy, or Parkinson's disease. * Individuals with neurological system disorders. * Individuals with alcohol or drug dependence. * Individuals with other major physical illnesses, such as diabetes, heart failure, or endocrine abnormalities, or those who have experienced an acute myocardial infarction within the past three months. * Individuals with metal objects in the body that cannot undergo magnetic resonance imaging (MRI), such as cardiac pacemakers, vascular clips, hearing aids, artificial joints, steel pins, etc. * Individuals with Claustrophobia. * Individuals in pregnancy or possibility of pregnancy.
Conditions Depressive Symptoms, Anxiety Symptoms, G...
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this randomized controlled trial (RCT) is to investigate the effectiveness of a culturally adapted internet-based cognitive behavioral therapy (i-CBT) intervention in reducing symptoms of common mental health issues among Farsi/Dari-speaking youth migrants and refugees. Investigator hypothesizes that there will be a significant decrease in psychological symptoms after participants receive the intervention compared to a control group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Culturally adapted i-CBT — A culturally and language adapted i-CBT intervention for Farsi/Dari speaking youth migrants and refugees. The intervention targets mild to moderate common mental health problems.

Primary Outcomes

  • Hopkins Symptom Checklist-25 (HSCL-25) (Pre-intervention, up to 5 weeks, immediately after the intervention, 6 months after completion of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-25
Completion: 2026-12-31
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Collaborators: Linkoeping University
Principal Investigators:
  • Gerhard Andersson, PhD (PRINCIPAL_INVESTIGATOR) - Linkoeping University
Contact Information
Study Contact:
Shervin Shahnavaz, PhD
0046722154769
shervin.shahnavaz@ki.se
Anahita Geranmayeh, MSc
0046737121661
Anahita.geranmayeh@ki.se
Shervin Shahnavaz, PhD
+46763238783
shervin.shahnavaz@ki.se
Karolinska Institutet
Interventions
  • Behavioral: Culturally adapted i-CBT — A culturally and language adapted i-CBT intervention for Farsi/Dari speaking youth migrants and refugees. The intervention targets mild to moderate common mental health problems.
Study Locations (1 sites)
Karolinska Institutet, Stockholm, 113 64 Sweden
Eligibility Criteria
Inclusion Criteria: * Between the ages of 15 and 29. * A score above the cut-off 1.75 on HSCL-25 * Has a refugee or migrant background * Has a good and stable internet connection * Has access to a computer, tablet or smartphone * Is fluent in reading and writing Arabic * Has the ability to dedicate time to take part in the intervention for 6-10 weeks. Exclusion Criteria: * Is suffering from a severe mental illness, such as psychosis or severe depression. * Is suffering from substance abuse * Is undergoing a psychological treatment * Has a high risk of suicide
Conditions Parkinson's Disease, Major Depressive Di...
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: 11C-UCB-J — Radiotracer for imaging
  • Drug: ketamine hydrochloride — There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.

Primary Outcomes

  • Montgomery-Åsberg Depression Rating Scale (MADRS) (One day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-01
Completion: 2029-12-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Contact Information
Study Contact:
Sophie Holmes
2036854066
sophie.holmes@yale.edu
Libby DiDomizio
2039476313
libby.didomizio@yale.edu
Sophie Holmes, PhD
203-685-4066
sophie.holmes@yale.edu
Yale University
Interventions
  • Radiation: 11C-UCB-J — Radiotracer for imaging
  • Drug: ketamine hydrochloride — There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.
Study Locations (1 sites)
Yale University, New Haven, Connecticut 06520 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 40-80. 2. For women of reproductive potential, a negative pregnancy test at screening and scanning 3. For PD patients, clinical diagnosis of PD, able to consent and tolerate PET procedures 4. For PD depression patients - at least moderate symptom severity as determined by at least 15 on the MADRS, which has shown maximum discrimination between depressed and non-depressed PD patients. 5. For dPD patients undergoing ketamine, abstinence from drugs of abuse, other than alcohol, cannabis, nicotine and caffeine for the duration of the study. Patients with substance use disorders as defined by the DSM-5 will be excluded. Exclusion Criteria: 1. Dementia (Montreal Cognitive Assessment (MoCA) score \<21) 2. A significant primary DSM-5 psychiatric disorder except for MDD 3. A history of or current significant medical (e.g. cardiovascular, renal), or neurological (e.g. cerebrovascular, seizure, traumatic brain injury) illness other than PD that is unstable and significantly increase their risk and/or might affect the study objectives, as determined by study physicians. 4. Prior radiation exposure for research purposes within such that participation in this study would place them over FDA limits for annual radiation exposure 5. Medications affecting SV2A availability (e.g. levetiracetam) 6. For dPD patients receiving ketamine, uncontrolled hypertension, defined as average blood pressure greater than or equal to 140 mmHg or an average diastolic blood pressure greater than or equal to 90 mmHg among those patients who have hypertension. 7. Contraindications to MRI. 8. For patients undergoing arterial sampling for the PET scan: Iodine allergy, bleeding disorder and/or use of blood thinning medication 9. Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.
Conditions Suicide Prevention
Phase NA
Enrollment 2100
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This implementation research project aims to test the effectiveness and implementation outcomes of suicide safety planning along and a transdiagnostic cognitive behavioral intervention for suicide prevention on decreasing suicidal behaviors in secondary school students in Mozambique. This study will also result in hypothesized mechanisms of intervention effects, costs and cost-effectiveness.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Safety Planning Intervention — All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
  • Behavioral: Enhanced Usual Care — All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
  • Behavioral: Transdiagnostic Cognitive Behavioral Therapy for Suicide Prevention — All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.

Primary Outcomes

  • Suicidal Behavior (6-months post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2028-12-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 2100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Bradley Wagenaar, PhD, MPH (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Morgan Turner, LICSW
206-543-8382
morgank2@uw.edu
Interventions
  • Behavioral: Safety Planning Intervention — All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
  • Behavioral: Enhanced Usual Care — All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
  • Behavioral: Transdiagnostic Cognitive Behavioral Therapy for Suicide Prevention — All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
Study Locations (7 sites)
9 Secondary Schools, Beira, Mozambique
1 Secondary School, Caia, Mozambique
1 Secondary School, Cheringoma., Mozambique
1 Secondary School, Chibabava, Mozambique
4 Secondary Schools, Dondo, Mozambique
1 Secondary School, Maringue, Mozambique
4 Secondary Schools, Nhamatanda, Mozambique
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for suicide risk screening: 1. Youth enrolled in a secondary school in Sofala Province that is located within 30 minutes of a health facility that hosts both an urgent care and mental health department. 2. Youth enrolled in 9th and/or 10th and/or 11th grade. 3. Legal guardian has provided consent to participate if under 18 or if youth is age 18 or older and has provided consent to participate. 4. Youth has assented to participation. Inclusion criteria for trial participation and allocation to study arm: 1\. Youth expresses active suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS). Exclusion Criteria: 1. Youth and/or guardian has not provided consent to participate, or responsible party is unable to provide informed consent. 2. Youth is not enrolled in a participating secondary school. 3. Youth declines to assent. 4. Youth is a ward of the State or any other agency, institution, or entity.
Conditions Prader-Willi Syndrome
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to help teens with Prader-Willi Syndrome (PWS) and their families learn practical strategies for managing issues like irritability, meltdowns, and anxiety. The main objective of the study is: To adapt current Regulating Together materials to create an outpatient group program for emotion dysregulation in Prader-Willi Syndrome (PWS) that will improve psychosocial outcomes for youth with PWS.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Regulating Together group therapy — Regulating Together is the original curriculum developed for autistic youth that uses evidence-based therapeutic strategies including relaxation techniques, parent management training, and mindfulness to help regulate emotions. This study will adapt the original Regulating Together curriculum to focus on behavioral interventions to treat emotion dysregulation in Prader-Willi Syndrome.

Primary Outcomes

  • Emotion Dysregulation Inventory - Reactivity (From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2027-01
Completion: 2027-11
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Mercy Hospital Kansas City
Collaborators: Foundation for Prader-Willi Research
Principal Investigators:
  • Walker McKinney, PhD (PRINCIPAL_INVESTIGATOR) - Children's Mercy
Contact Information
Study Contact:
Grayson Manley, RN
816-816-6967
gmanley@cmh.edu
Grayson Manley, RN
816-816-6967
gmanley@cmh.edu
Children's Mercy
Walker McKinney, PhD
816-234-3656
wsmckinney@cmh.edu
Children's Mercy
Interventions
  • Behavioral: Regulating Together group therapy — Regulating Together is the original curriculum developed for autistic youth that uses evidence-based therapeutic strategies including relaxation techniques, parent management training, and mindfulness to help regulate emotions. This study will adapt the original Regulating Together curriculum to focus on behavioral interventions to treat emotion dysregulation in Prader-Willi Syndrome.
Study Locations (1 sites)
Children's Mercy, Kansas City, Missouri 64108 United States
Eligibility Criteria
Child Participant Inclusion Criteria: * Ages 13-17.5 years * Confirmed genetic diagnosis of Prader-Willi Syndrome * Fluent in spoken English * Adolescent's use of flexible phrase speech or greater * Meeting clinically significant emotional dysregulation criteria * Willing to participate in weekly 90-minute group sessions * Family is willing to keep prescribed psychiatric medication and outside behavioral interventions stable * Parent, guardian, or legally authorized representative must provide written permission on behalf of the participant Child Participant Exclusion Criteria: * Initiation of new psychosocial intervention within 30 days prior to first day of treatment * Presence of physical aggression in the adolescent directed towards a peer outside the home that resulted in injury within 30 days prior to screening * Presence of comorbid major neuropsychiatric illness warranting other treatment approaches * Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss Caregiver Inclusion Criteria: * Age ≥ 18 years * Lives and cares for their child with PWS for \> 50% of the year * Fluent in spoken English * Willing to participate in twice weekly 90-minute sessions, including one virtual session weekly Caregiver Exclusion Criteria: -Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 145
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and/or zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without diminishing treatment effectiveness in hospitalized patients with depression. The investigators hypothesize that blockade of the GABA receptor with flumazenil will reduce cognitive side effects through improved seizures and a reduced need for electrical charge escalation during the ECT series. Cognitive side effects will be measured by the total score on the Screening for Cognitive Impairment in Psychiatry (SCIP) (primary outcome) at follow-up after completion of the ECT series. Furthermore, it is expected that the flumazenil strategy will reduce pre-treatment anxiety and improve patient satisfaction (secondary outcomes). In addition, flumazenil strategy is hypothesized to have beneficial effects on subjective cognitive complaints, autobiographical memory, and executive functioning (secondary outcomes). Finally, the flumazenil strategy is expected to be associated with more favorable structural and functional changes in executive functioning and memory-related brain networks after completion of the ECT series, which may, in turn, be linked to better overall cognition and autobiographical memory (secondary outcome measures). For exploratory purposes, the study will also examine longitudinal changes in depressive symptoms and cognitive outcomes from baseline to follow-up (tertiary outcomes). Investigators will compare two different pre-ECT benzodiazepine management strategies: 1. Flumazenil strategy (experimental): continued benzodiazepine and/or zopiclone use up until the time of the ECT session, followed by administration of flumazenil immediately prior to ECT 2. Benzodiazepine withholding strategy (treatment as usual): discontinuation of benzodiazepines and/or zopiclone prior to the ECT in accordance with standard clinical practice

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Flumazenil — The intervention involves continuation of benzodiazepine and/or zopiclone treatment up to the time of ECT, followed by administration of flumazenil immediately prior to anesthesia to transiently reverse the effect of benzodiazepines and/or zopiclone. Otherwise, ECT is administered according to standard clinical procedures.
  • Procedure: Electroconvulsive therapy (ECT) — Standard ECT treatment performed in accordance with clinical practice, with benzodiazepines and/or zopiclone withheld after 5:00 p.m. on the day before each session

Primary Outcomes

  • Screen for Cognitive Impairment in Psychiatry (SCIP) (Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-15
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 145 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anders Jørgensen
Principal Investigators:
  • Anders Jørgensen, MD, Ph.D. (PRINCIPAL_INVESTIGATOR) - Mental Health Services of the Capital Region
Contact Information
Study Contact:
Stella K. S. Lystlund, MSc in Psychology
+ 45 21 35 40 55
stella.klara.soerensdottir.lystlund@regionh.dk
Yunus Kiros, MD
+ 45 81 71 95 29
yunus.kiros.02@regionh.dk
Interventions
  • Drug: Flumazenil — The intervention involves continuation of benzodiazepine and/or zopiclone treatment up to the time of ECT, followed by administration of flumazenil immediately prior to anesthesia to transiently reverse the effect of benzodiazepines and/or zopiclone. Otherwise, ECT is administered according to standard clinical procedures.
  • Procedure: Electroconvulsive therapy (ECT) — Standard ECT treatment performed in accordance with clinical practice, with benzodiazepines and/or zopiclone withheld after 5:00 p.m. on the day before each session
Study Locations (1 sites)
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Capital Region 2000 Denmark
Eligibility Criteria
Inclusion criteria: * Current depressive episode (unipolar or bipolar), corresponding to ICD-10 codes F31.3-5, F32 or F33. * Admitted at a study affiliated department in the Mental Health Services of the Capital Region of Denmark * Referred to ECT by the regular psychiatrist and has given consent to ECT * Currently receiving treatment with a benzodiazepine and/or zopiclone, at a minimum daily dose equivalent to 0.5 mg lorazepam. Exclusion criteria: * Involuntary treatment with ECT * Known gross abnormalities in brain structure deemed likely to influence cognitive functioning * Pregnancy or breast-feeding * Inability to read or understand Danish * Acute organic brain disease (e.g., delirium) influencing the ability to give informed consent * Any pre-existing condition associated with an increased risk of prolonged or uncontrollable seizures, including but not limited to epilepsy or alcohol- or benzodiazepine withdrawal states * Conditions associated with reduced metabolism of flumazenil (e.g., liver failure)